Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
中国国家自然科学基金; 芬兰科学院;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [41] Real-World Comparison of Progression Free Survival and Time to Next Therapy Endpoints in Newly Diagnosed Patients With Multiple Myeloma
    Mutterback, Erin
    Mian, Hira
    McCurdy, Arleigh
    Cipkar, Christopher
    Sapru, Hyra
    Fonseca, Rafael
    Visram, Alissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S237 - S238
  • [42] Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 81 - 87
  • [43] Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT
    Ho, Christine M.
    McCarthy, Philip L.
    Wallace, Paul K.
    Zhang, Yali
    Fora, Ahmad
    Mellors, Patrick
    Tario, Joseph D.
    McCarthy, Benjamin L. S.
    Chen, George L.
    Holstein, Sarah A.
    Balderman, Sophia R.
    Cao, Xuefang
    Paiva, Bruno
    Hahn, Theresa
    BLOOD ADVANCES, 2017, 1 (15) : 1056 - 1066
  • [44] Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma
    Mukul Aggarwal
    Narendra Agrawal
    Neha Yadav
    Priyanka Verma
    Rayaz Ahmed
    Pallavi Mehta
    Jyotsna Kapoor
    Dinesh Bhurani
    Annals of Hematology, 2018, 97 : 1869 - 1877
  • [45] Newly diagnosed multiple myeloma patients with 1q21 amplification treated by autologous stem cell transplantation have shorter progression-free survival interval.
    Nemec, Pavel
    Greslikova, Henrieta
    Kuglik, Petr
    Filkova, Hana
    Zaoralova, Romana
    Vranova, Vladimira
    Smejkalova, Jana
    Vidlakova, Petra
    Oltova, Alexandra
    Hajek, Roman
    BLOOD, 2007, 110 (11) : 263B - 263B
  • [46] Minimal Residual Disease Status Predicts Progression-Free Survival in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (KRd)
    Jasielec, Jagoda
    Dytfeld, Dominik
    Griffith, Kent A.
    McDonnell, Kathryn
    Lebovic, Daniel
    Kandarpa, Malathi
    Anderson, Tara
    Mietzel, Melissa
    Faham, Malek
    Lee, Liana
    Levy, Joan
    Alonge, Mattina
    Rosebeck, Shaun
    Kaminski, Mark
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [47] Risk of mortality in COVID-19 patients with newly diagnosed and pre-existing diabetes
    Sathish, Thirunavukkarasu
    PRIMARY CARE DIABETES, 2022, 16 (01) : 214 - 214
  • [48] Impact of interferon maintenance therapy on multiple myeloma patients' quality of life, progression-free survival and overall survival
    Bumeder, I
    Tyroller, M.
    Fischer, N.
    Busch, R.
    Frick, E.
    PSYCHO-ONCOLOGY, 2006, 15 (02) : S187 - S188
  • [49] Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy
    Migkou, Magdalini
    Kastritis, Efstathios
    Roussou, Maria
    Gkotzamanidou, Maria
    Gavriatopoulou, Maria
    Nikitas, Nikitas
    Mparmparoussi, Despina
    Matsouka, Charis
    Gika, Dimitra
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (04) : 323 - 329
  • [50] Pre-Existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk
    Kim, Jihoon Andrew
    Choi, Seulggie
    Choi, Daein
    Park, Sang Min
    DIABETES & METABOLISM JOURNAL, 2020, 44 (02) : 307 - +